

## Access to healthcare

Summary table: Our Access Programmes at a Glance

<b>Project</b>	<b>Objective</b>	<b>Progress in 2008</b>
Clinical trial programmes	We provide free medicines and tests to patients in phase I-IV clinical trials. This often includes additional treatment and tests other than those being trialled. Hospitals and clinics are compensated for hosting the trials, and often use the money to fund additional nursing staff, education centres and research. Phase IV (postapproval) trials familiarise clinicians with new drugs before they become widely available.	In 2008, over 235,000 patients worldwide gained access to innovative treatments by taking part in phase I-IV trials.
Clinical trial protocol registry & trial results database	Launched in April 2005, our clinical trial protocol registry and results database provides information about all new Roche-managed trials, plus key results from completed phase I-IV trials. Roche trials are also logged in the US National Institutes of Health's Clinical Trials Registry.	As of 2008, 574 pharmaceutical protocols, 27 diagnostics protocols and 216 trial results have been published on the website.
Patient assistance programmes	In the US, we support several patient assistance programmes that provide free medicines for people who need them but have inadequate or no health insurance. These include the Roche Patient Assistance Programme and the Partnership for Prescription Assistance.	In 2008, over 38,000 patients in the US benefited from Roche and Genentech Patient Assistance Programmes.
Patent and pricing policies  <i>www.roche-hiv.com</i>	We don't enforce existing patents or apply for new patents for any of our medicines in the world's least developed countries or any sub-Saharan African countries. We supply our HIV/AIDS treatments at no-profit to these countries. We also supply drugs at reduced prices in low-and lower middle-income countries.	Our no-profit prices apply to more than 23 million people in 63 countries, covering 71% of all people living with HIV/AIDS in Least Developed Countries. Including low- and lower middle-income countries, reduced prices are offered to 88% of all people living with HIV/AIDS.
Accelerating Access Initiative (AAI)	Roche is a founding member of the AAI, a partnership between nine research-based pharmaceutical companies and five UN agencies that aims to increase access to HIV/AIDS medicines in developing countries.	AAI efforts have started to deliver. A growing number of patients are on treatment in the developing world, as reported by UNAIDS.
<a href="#">AmpliCare</a>	The AmpliCare programme began in 2002 and supplies HIV viral load tests at the lowest possible price to sub-Saharan Africa, South America and the Least Developed Countries defined by the UN. AmpliCare also offers an education programme to keep local doctors and nurses fully informed about the latest advances in HIV/AIDS care.	In 2008 in sub-Saharan Africa, 450,000 infants were tested for HIV and an estimated 560,000 patients had their HIV/AIDS treatment monitored.

Project	Objective	Progress in 2008
<a href="#">Phelophepa Health Care Train</a>	This is a mobile clinic delivering medical care to remote parts of South Africa. Many patients call it the 'train of hope'. It has 16 coaches and is equipped to supply general, dental, eye and psychiatric care as well as cancer screening tests and diabetes prevention. Roche has provided funding for the train since it began running in 1994.	Since 1994, around 600,000 people have been treated in the train's various clinics. A further nearly 1.3 million people have attended school screening, health education and counselling workshops. More than 40,000 patients in the most remote parts of the country register for treatment each year.
<a href="#">Technology Transfer Initiative (TTI)</a>	The TTI was launched in 2006 to give companies in the least developed countries and sub-Saharan Africa free, on-site technical help to manufacture generic versions of our HIV medicine.	We signed agreements with four manufacturers in Bangladesh, Kenya, Tanzania and Zimbabwe in 2008. We also expanded the TTI to include training seminars on good manufacturing practices. Ten manufacturers have signed up since the TTI was launched in 2006.
NGO Pilot Training Scheme	The Roche Centre for Applied Development is partnering with NGOs to help them build healthcare capacity in developing countries.	In October 2007, we began publicising the availability of a scheme to sponsor pharmacists and doctors from Least Developed Countries to spend between three and six months at a Roche clinical pharmacology unit. Trainees will use their new skills to manage clinical trials in their own countries.
Working with public health organisations	Roche is working with international public health organisations to help increase access to laboratory services.	Together with organisations such as the Clinton Foundation HIV/AIDS Initiative, we are providing sustainable diagnostic solutions for early infant diagnosis in 35 resource-limited countries. Other initiatives include HIV monitoring for patients on government ARV programmes, the development of screening techniques for tuberculosis and resistant strains, and capacity building initiatives such as our training academies.
<b>Home away from home</b>	Roche is working with the National Foundation for Transplants (NFT) in the USA to sponsor free hotel stays to transplant patients and families in need of accommodation related to pre-and post-transplant care.	The program continued in 2008, with Roche donating accumulated corporate hotel points to the NFT for patients and their families.
<a href="#">CARE programme</a>	This partnership between Roche and the PharmAccess Foundation has helped make HIV/AIDS treatment sustainable by strengthening local health systems and training African healthcare workers to care for people	We hosted the fifth CARE training event for African healthcare workers in April 2008. The seven-year partnership has now reached its conclusion, with training

Project	Objective	Progress in 2008
	affected by the disease.	delivered to over 600 African healthcare workers.
<a href="#">Cambodian Treatment Access Programme (CTAP)</a>	<p>CTAP was established in 2003 as a unique public-private partnership between the Cambodian Ministry of Health, the National Centre in HIV Epidemiology and Clinical Research at the University of New South Wales in Australia, and Roche.</p>	<p>Support provided by Roche has enabled drugs, diagnostics and training to be supplied, which resulted in CTAP successfully enrolling more than 2,200 men, women and children infected with HIV/AIDS at the clinic, and providing care and treatment free of charge to more than 1,400 patients.</p> <p>In addition to providing the funding, HIV therapy and viral load tests, our support has also facilitated the documentation of the outputs to support advocacy for international resources for anti-retroviral provision.</p> <p>The programme has also provided HIV/AIDS training, which involved 400 Cambodian clinicians, reinforcing the aim of the CTAP training programme to facilitate the national expansion of HIV care.</p>
Pandemic planning	<p>The World Health Organisation (WHO) warns that the next global influenza pandemic is imminent. Roche has been doing all it can to ensure adequate worldwide stocks of its influenza drug Tamiflu for pandemic stockpiling, without restricting the treatment of seasonal flu.</p>	<p>Tamiflu production capacity was increased by almost 15-fold from 27 million courses of treatment in 2004 to over 400 million treatment courses annually. Production has now been tailored to meet demand. Five million treatment courses have been donated to the WHO as a stockpile to limit the impact of a pandemic.</p>
WHO Special Programme for Research and Training in Division for Tropical Diseases	<p>Roche is helping the WHO's Division for Tropical Diseases (TDR) to train their researchers, clinical monitors and ethics committees in compliance, good clinical practice and quality assurance.</p>	<p>In 2007, Roche ran a series of workshops on auditing and quality assurance for researchers managing and monitoring WHO sponsored trials on tropical diseases. On behalf of the WHO, Roche also audited WHO trials of leishmaniasis, pulmonary TB and trypanosomiasis, participated in "surveys" of ethics committees and supported training events in sub-Saharan Africa and Asia Pacific.</p>
Institute of OneWorld Health collaboration	<p>This research collaboration aims to increase research into neglected diseases.</p>	<p>Launched in 2008, the collaboration allows OneWorld health to screen compounds from the Roche library to</p>

Project	Objective	Progress in 2008
		identify new drugs for treating acute diarrhea.
Health Partners International of Canada (HPIC)	HPIC is a humanitarian organisation that provides medical products donated by Canadian healthcare companies for aid, relief and development projects in some of the world's poorest countries.	Roche Canada is a long-standing sponsor of HPIC's Physician Travel Packs, used to provide medical aid to the developing world.